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Abstract
Multiple and complex pathways promote the deleterious
effects of hyperglycemia in diabetes, ultimately leading
to micro- and macrovascular disease. Some of the
known mechanisms in diabetic vascular disease may
explain the initiation of the “metabolic memory”,b u t
fall short if long periods of time are involved.
Vascular research has been prolific in the past in find-
ing links between microvascular dysfunction and subse-
quent macrovascular disease. Thus, this text will extend
the current discussion of the “metabolic memory” by
including available data from vascular research.
The hypothesis proposes that structural and functional
changes in the microcirculation interact within the vas-
cular continuum with larger arteries. This interaction
may lead to subsequent upstream endothelial dysfunc-
tion, atherosclerosis and vascular complications ("Micro/
Macro Interaction”). The underlying microvascular
structural changes may be more long-term and possibly
mediate the “metabolic memory”.
This hypothesis, that the “not-so new” interaction
between micro-and macrovasculature may promote
“metabolic memory” effects extends and unifies cur-
rently discussed theories.
The vascular perspective of the metabolic
memory
In vascular research it is well established, that microvascu-
lar dysfunction eventually leads to subsequent macrovas-
cular disease [1]. A dilation of prearterioles and arterioles
results in an increase of shear stress, which triggers flow
dependent dilation in conductance arteries [1,2], less shear
stress secondary to microvascular dysfunction may lead to
less vasodilation and thus endothelial dysfunction in
conductance arteries.
In diabetes, hyperglycemia promotes both micro- and
macrovascular damage by activating a network of multi-
ple and complex pathways. Many of these may explain
the initiation of the “metabolic memory” but fall short if
long periods of time are involved. Structural changes in
the microcirculation alter microvessels and their func-
tion, resulting in microvascular endpoints in the most
susceptible organs.
The interaction within the vascular continuum between
microvessels and larger arteries may lead to subsequent
upstream endothelial dysfunction, atherosclerosis and
vascular complications ("Micro/Macro Interaction”).
In addition local intra vessel wall microvascular changes
can promote localized atherosclerosis. These underlying
microvascular structural changes may be more long-term
and possibly mediate the “metabolic memory”. The fact,
that early intensive treatment of diabetes may be superior
to intensification at a later disease stage indicates an early
time window one has to make use of for intensive ther-
apy in order to achieve a long-lasting therapeutic benefit
by signifying the role of a structural fixation up to a
“point of no return”, when a regression of vascular
disease progression is no longer possible. This extended,
or rather unifying hypothesis will promote new research
in this exiting area.
Good metabolic control mediates long-term
benefit
One of the major principles of the clinical long-term
management of patients with diabetes mellitus is to pre-
vent cardiovascular (CV) complications. Recently it was
observed in several large scale clinical trials, that an
intensive antihyperglycaemic treatment of diabetic
patients, both in type 1 and 2, reduces the incidence of
microvascular complications [3-5]. After the end of each
study the participants were followed without any further
intervention and, despite no further treatment differ-
ences, the advantage of intensive antidiabetic treatment
persisted and even extended to a reduction of macrovas-
cular events. The underlying cause of this phenomenon
remains unclear; it is currently being discussed to be a
“metabolic memory” e f f e c t :Ad e f i n e dp e r i o do fg o o d
metabolic control conciliates a long term beneficial
effect on cardiovascular endpoints. Several hypotheses,
in particular the effects of a prolonged decreased
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extends the present view by introducing the role of
macro- and microvascular interaction as a possible
cause mediating “metabolic memory”.
The global epidemic of diabetes leads to growing
numbers of secondary cardiovascular complications.
Cardiovascular mortality affects the majority of diabetic
patients, the relative risk as compared to a non-diabetic
population is several fold higher [6,7].
Tight metabolic control is the obvious approach to
reduce the rate of cardiovascular events. Two very
recent trials, ACCORD and ADVANCE, triggered a dis-
cussion, whether very tight metabolic control is really
beneficial or not even contra productive [8,9]. Both trials
explored in a large number of diabetic patients, whether
an aggressive treatment algorithm to achieve good meta-
bolic control can reduce micro- and/or macrovascular
endpoints. The ADVANCE trial, although not finding a
reduction of macrovascular endpoints, could show a
reduction of diabetic nephropathy [8]. ACCORD was
prematurely stopped because of higher mortality in the
intensive treatment arm [9]. The underlying cause of
these findings now is a matter of intense and controver-
sial discussion. Both studies included diabetic patients
with a history of cardiovascular disease, thus a more
“advanced” subset of patients, in which the disease pro-
cess might not be reversible.
Two other landmark studies showed differing results
with regard to cardiovascular outcome [4,5]: although
the initial results of the UKPDS study in newly diag-
nosed type 2 diabetic people [5] showed an improve-
ment only in microvascular endpoints in the intensive
treatment arm, the follow-up observation of another 10
years could also show a reduction of macrovascular end-
points and CV mortality in this group [4], despite of
equal metabolic control (HbA1c) of both treatment
arms after the end of the initial treatment period. The
DCCT/EDIC trials showed very similar results for type
1 diabetic patients [3,10], including 1441 patients with a
maximum of 5 years of type 1 diabetes and no
complications.
The results of these studies led to a number of con-
clusions and new hypotheses, among which the concept
of “metabolic memory” stands out. This hypothesis
describes the observation that a prolonged tight meta-
bolic control during early (newly diagnosed to 5 years)
but not at later stage diabetes mellitus leads to sustained
beneficial effects regarding micro- and macrovascular
endpoints [3-5,10,11]. An earlier work by Garvey and
co-workers [12] provided evidence for potential
mechanisms. They demonstrated that an intensive insu-
lin regimen in type 2 diabetic patients reversed the insu-
lin resistance in muscle and liver as well as increased
the beta cell insulin secretion without further use of
insulin, claiming, that this would be caused by some
“metabolic memory”. In the present discussion the term
“metabolic memory” implies that early glycaemic envir-
onment is “remembered” by target organs such as blood
vessels, but also retina, heart, kidney, etc.[13]. The evo-
lution of this concept has been recently discussed by
Ceriello et al [13]. Briefly, the first reports of Kern
reported two decades ago in a diabetic dog model, that
poor glycaemic control followed by a period of good
control did show the same rate of retinopathy as poorly
controlled dogs [14]. Interestingly, Roy showed a shift of
gene expression towards collagen IV and fibronectin
expression in vitro (endothelial cells) and in diabetic
rats (kidney cortex and myocardium) [15] with a similar
design of a period with poor control followed by nor-
malized glucose levels. These data implied that irreversi-
ble structural changes m i g h tb ei n v o l v e di nt h e
progression of late-term hyperglycaemic effects.
The potential role of oxidative stress
Hyperglycemia induces a large number of alterations at
the cellular level of vascular tissue that potentially accel-
erate the atherosclerotic process. Three major processes
are thought to interrelate and promote vascular changes,
which include glycolysation of proteins, oxidative stress
and protein kinase C activation [16]. There exists a
wealth of literature that highlights the role of oxidative
stress in the development of vascular damage and subse-
quent atherosclerosis. Details are not within the scope of
this paper and can be found elsewhere [17].
The potential relation between oxidative stress and the
“metabolic memory” is presently the most discussed
hypothesis [13]. This concept implies that a sustained
exposure to reactive nitrogen and oxygen species
(RNOS), mediates multiple downstream biological pro-
cesses via covalent modification of proteins, nucleic
acids and/or lipoproteins, which finally accounts for
irreversible deterioration. On the other hand, a transient
RNOS production on the short-term is an integral part
of cellular signal transduction under physiological condi-
tions [13].
Although this hypothesis is compelling, it would not
explain an effect, that according to EDIC and UKPDS
“metabolic memory” extends to beyond 10 years. To
explain macrovascular disease these mechanisms would
have to occur within the vessel walls of the macrovascu-
lature, especially within the endothelium as the central
cellular compartment of early atherosclerotic develop-
ment. One could argue that early RNOS overload
primes for the later development of macrovascular dis-
ease, since atherosclerosis is generally not reversible.
Several recent papers explore the possibility of epige-
netic changes induced by hyperglycemia.. El-Osta and co-
workers were able to show that transient hyperglycemia
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tic endothelial cells in vitro and in vivo in non-diabetic
mice [18,19]. Various methylation or dymatylation events
may lead to upregulation of NFB-p65, which may lead to
subsequent activation of pro-inflammatory pathways,
possibly leading to micro- and macrovascular disease [20].
Tonna et al propose the involvement of epigenetic changes
especially for the development of diabetic nephropathy
[20]. Although this approach is very compelling, more in
vivo data will be needed. As vascular endothelium is an
organ with a high turnover and regenerative capacity
[21,22], the question remains unanswered how early
endothelial changes mediated through oxidative stress
and/or epigenetic changes can account for long-term
macrovascular risk. Additionally, multiple mechanisms
including induction of an antioxidative response and
counter regulation of gene expression exist to maintain
endothelial integrity [23-26].
Reality is probably more complex and thus the current
hypothesis of the “metabolic memory” may be extended
by (re-)introducing a vascular perspective. A central
observation of EDIC and UKPDS is, that diabetic people
who were recruited early in their disease career (newly
diagnosed to 5 years), despite of treatment modalities,
first presented with microvascular disease only whereas
macrovascular disease occurred much later. Patients
with intensive treatment developed less micro- and later
also less macrovascular disease. These simplified obser-
vations may lead to the conclusion that there is a timely
order, and that microvascular disease may be a prerequi-
site for macrovascular complications in these patients.
Micro- and Macrovasculature
The above findings are supported by observations that
microcirculatory changes correlate with macrovascular
atherosclerosis and the occurrence of cardiovascular
events. Wong and co-workers found in the “Athero-
sclerosis Risk in Communities"-study (ARIC), that ret-
inal arteriolar narrowing as an established marker of
microvascular damage is closely associated with the risk
of events related to coronary heart disease [27].
Although these effects were predominantly seen in
women, they were independent of hypertension and dia-
betes mellitus. Other studies conformed this association
between retinal changes and risk for coronary artery dis-
ease in general [28], micro-and macrovascular changes
in diabetes [28,29], subclinical atherosclerotic disease
[28] and the risk of stroke [28,30-32].
It is important to realize, that microvascular dysfunc-
tion is not limited to one organ but rather a systemic
process [33,34]. In hypertension for example histopatho-
logical changes in retinal and coronary arteries are very
similar [35,34,33]. There also exists a microangiopathic
process within the vessel wall of conduit arteries
resembling that of retinal changes [36], which are dis-
cussed to precede macrovascular changes. Thus micro-
vascular changes in a particular vascular bed (e.g. retinal
arterioles) may allow comparisons to other vascular
regions.
Fibrosis of the microvascular interstitium
Besides of functional changes of the microcirculation
structural changes are mediating long term complications.
As mentioned above, it is well established that hypergly-
caemia mediates vascular changes through several path-
ways [37]. These pathways are interconnected with each
other and include the increased synthesis of sorbitol and
hexosamines, glycosylation of proteins, synthesis of
“advanced glycosylation end products” (AGE), and oxida-
tive stress (figure 1). The downstream effects in the micro-
vasculature are mainly characterized by changes of the
extracellular matrix composition and structure. Induction
of inflammatory processes through receptor binding of
AGEs or oxidative stress mediate changes of the structure
of the extracellular matrix [37]. Subsequent fibrosis and
the extension of extracellular structures impair capillary
blood flow and in particular reduces capillary density
(figure 1) [38-40]. Reduced blood flow may then facilitate
microvascular complications. These become apparent the
earliest in the most vulnerable organs, which are, among
others, retina and kidney. Early diabetic microvascular
changes relate to a thickening of the basement membrane
in the capillaries. These changes occur throughout the
whole body and include arterioles in the glomeruli, retina,
skin, muscle, and myocardium, resulting in classic diabetic
microangiopathy [41]. Various mechanisms have been
proposed for diabetic microvascular complications [41],
but the endothelium plays a major role in the disease
processes. Surprisingly, endothelial cells show a high het-
erogeneity in structure and function throughout the vascu-
lar tree [42-44]. This relates to a variety of functional
differences between different vascular beds, such as
permeability, hemostasis, vasomotor tone, leukocyte trans-
migration and others. These may, at least in part, explain
the susceptibility of certain organs to diabetic microvascu-
lar damage.
The vascular continuum: Interaction between
micro- and macrovasculature
Conductance arteries provide sufficient blood flow to
end organs, but blood demand is not regulated through
dilatation of the larger arteries but rather through the
alteration of microvascular resistance [45]. This function
is located within the specific organ at the level of the
resistance arteries or arterioles (figure 2). The microcir-
culation regulates vasomotion and permeability and can
thus adapt blood flow according to local metabolic
needs [46,47].
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Page 3 of 8Figure 1 Hyperglycemia and vascular outcome. Hyperglycemia activates multiple and complex pathogenetically relevant pathways.
Inflammatory processes lead to a thickening of the basal membrane of microvessels and perivascular fibrosis resulting in microvascular
endpoints in the most susceptible organs, such as renal insufficiency and retinopathy. The structural changes also result in functional impairment
and a reduction in blood flow regulation, which in turn reduces macrovascular endothelial function ("Micro/Macro Interaction”). The loss of
endothelial protection may lead to the subsequent development of atherosclerosis. The structural changes within the microcirculation may
account for building up a “metabolic memory”.
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well studied, under physiological conditions is mainly
regulated through microvessels; conductance vessels
only participate with about 5% to total coronary resis-
tance [45,48-50]. A common misperception may be that
there is only little or no interaction between macro- and
microcirculation and vice versa, but rather the opposite
is the case. Macrovasculature can influence downstream
resistance arteries through several pathways: A hemody-
namically relevant stenosis > 50% of lumen reduction
can be compensated through lowering downstream vas-
cular resistance metabolically (e.g. for maintenance of
oxygen supply) [51,52]. This reduces the amplitude of
the flow reserve, so that if needed, flow reserve may not
be sufficient for adequate supply of the end organ,
which may in turn lead to symptoms such as angina
pectoris in the heart [53,54]. Also, repeated microembo-
lisms may alter downstream vascular resistance
(reviewed in [45]).
On the other hand microvasculature may also influ-
ence the function of upstream larger arteries. Patients
with hypertensive heart disease present with a substan-
tially reduced coronary flow reserve [55]. Coronary
microangiopathy is associated with a reduction of
upstream dilatatory function of epicardial coronary
arteries [56]. This association is correlated to the degree
of myocardial hypertrophy. The interface may, again, be
endothelial function. Vasodilatory capacity of large
Figure 2 The Vascular Continuum. Conductance arteries mediate downstream effects to resistance arteries and capillaries. If microcirculation is
impaired by perivascular fibrosis as in diabetes, upstream effects influence conductance arteries.
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nitric oxide synthesis of endothelial cells. Shear stress is
one of the major regulators of local NO-synthesis. In
principle, an increase of a normal microcirculatory flow-
reserve will increase upstream flow mediated vasodila-
tion by a factor 3-6 [45,57]. Microvascular dysfunction
with a reduced flow reserve will lead to a reduced shear
stress-induced NO synthesis in upstream macrovessels
[58]. This implies that structural changes such as peri-
vascular fibrosis of microvessels can directly influence
upstream arteries and cause endothelial dysfunction
(over time) and subsequent atherosclerosis (figures 1
and 2). This proposed mechanism may represent the
cause of the “metabolic memory”. Since the effect was
only seen in diabetic patients who were included in
studies shortly after their diagnosis, microvascular struc-
tural changes might represent a “point of no return”,
after which an intensive treatment might less effective
or not effective at all. (figure 1).
Indirect studies suggest that a long-term reduction of
microcirculatory function would lead to endothelial dys-
function and consequent atherosclerosis. Kelm and cow-
orkers studied 62 hypertensive patients with myocardial
microangiopathy and without any macrovascular coron-
ary artery disease (CAD) for 10 years [45]. 28 patients
developed relevant coronary artery disease, which would
be the equivalent of an incidence for CAD of 8%. This
is multiple times higher than the yearly incidence of
CAD in American (0.37%) or Australian (0.11%) popula-
tions [45]. The risk of major cardiac events was 2- 3
fold higher.
In a recent review Oresanu and Plutzky hypothesize,
that microangiopathy in the neovasculature of vaso
vasorum may propagate and accelerate diabetic athero-
sclerosis [41]. The vaso vasorum is a network of micro-
vessels in the adventitia and media of large arteries [59]
providing the vascular wall of these large arteries with
nutrients but also influence lipid deposition and meta-
bolism and neurohumoral factors [59]. Hypoxia and
macrophages within atherosclerotic plaques may
promote intraplaque and intra vessel wall angiogenesis
and alter vessel wall microcirculation [36]. This hypoth-
esis would supplement the theory of this paper, in parti-
cular the occurrence of plaques at certain, rather
specific locations such as bifurcations.
In addition, several authors suggested, that microvas-
cular structure I not only the site of vascular resistance
but probably also the origin of most of the wave reflec-
tions generating increased central blood pressure and
thus influencing large artery stiffness [60]. Small artery
remodelling can be observed in hypertensive diabetics as
well as in patients with diabetes mellitus alone, under-
l i n i n gt h er o l eo fd i a b e t e sf o rt h ep a t h o p h y s i o l o g yo f
microvascular disease [61-63]. Drugs that somehow
improve microvascular structure are also effective
for improving the mechanical properties of large
arteries [62]
Conclusion
Although diabetes specific data is not yet available, there
exist strong analogies to hypertensive vascular disease,
which will allow well designed experiments and trials to
test this hypothesis. It could be possible that microvas-
cular events in the earlier course of the disease process
may be reversible through adaption processes whereas
m a c r o v a s c u l a rc h a n g e sm a yb em o r ei r r e v e r s i b l e
through maladaptation.
Proof-of-concept studies as well as clinical studies will
be needed to support this unifying concept, but a better
understanding of the interplay of metabolism, micro-
and macrovasculature may ultimately promote new ther-
apeutic options and better patient outcome.
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